Business
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 -- -- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 CaMMouflage r/r MM Phase 1 dose escalation dataset expect
About this update from Caribou Biosciences, Inc.
[{"type":"image","alt":"Caribou Biosciences, Inc.","displaySize":"","headline":null,"caption":"Caribou Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Rnd4qeRJ_xjp9Qy6VyL25w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c","width":300,"height":74}},"lazy":false},{"type":"text","content":"-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 --","length":144,"tagName":"p"},{"type":"text","content":"-- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 --","length":102,"tagName":"p"},{"type":"text","content":"-- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design --","length":189,"tagName":"p"},{"type":"text","content":"-- CB-011 CaMMouflage r/r MM Phase 1 dose escalation dataset expected to include recommended doses for expansion --","length":115,"tagName":"p"},{"type":"text","content":"BERKELEY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced a strategic pipeline prioritization with workforce and cost reduction initiatives to focus resources on its lead oncology clinical programs CB-010 and CB-011, with clinical data disclosures now planned for H2 2025.","length":399,"tagName":"p"},{"type":"text","content":"“Broad patient access to life-changing CAR-T cell therapies is only achievable if healthcare systems have an off-the-shelf option. Caribou’s two lead Phase 1 clinical programs, CB-010 for large B cell lymphoma and CB-011 for multiple myeloma, continue to demonstrate encouraging efficacy and have the potential to serve this critical unmet need for individuals living with hematologic malignancies,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “We recognize the challenges in the current market environment and believe the best approach is to present the most robust datasets for both prog...